(Q36821354)

16 August 2017

1 reference

title

Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients (English)

1 reference

16 August 2017

1 reference

1 reference

Stephanos J Hadziyannis

series ordinal

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

777-786

1 reference

Hepatitis B: an important public health issue

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

New developments in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Review article: current management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Liver transplantation in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Hepatitis B--preventable and now treatable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

The maze of treatments for hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Natural history and prognosis of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Emerging treatments in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Entecavir for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

AASLD 2005 distinguished achievement award to Dr. Jenny Heathcote.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.777

10.1517/13543784.16.6.777

21 January 2018

Identifiers

DOI

1 reference

release_5roh6zagrfdqdlez77xvw5gi5i

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5roh6zagrfdqdlez77xvw5gi5i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference